Details of Disease

Disease Name

Bacterial arthritis

infectious arthritis; pyogenic arthritis; septic arthritis

Definition

The inflammation of one or more joints caused by a bacterial infection within the joint space. Symptoms include pain, stiffness, and decreased range of motion in the affected joint.

Disease Hierarchy

DIST1YEL: Arthritis

DIS5QJ9S: Bacterial infection

DIS8YJPR: Infective arthritis

DIS8R241: Bacterial arthritis

Disease Identifiers

MONDO ID

MONDO_0004471

MESH ID

D001170

UMLS CUI

C1692886

MedGen ID

308434

SNOMED CT ID

48245008

General Information of Disease (ID: DIS8R241)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Cefotaxime	DMEB837	Approved	NA	[1]
Ceftriaxone	DMCEW64	Approved	Small molecular drug	[2]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 2 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ACLY	TT0Z6Y2	Strong	Biomarker	[3]
PPP3CA	TTA4LDE	Strong	Biomarker	[4]
------------------------------------------------------------------------------------

This Disease Is Related to 5 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
SUMF2	OT37I8JL	Limited	Biomarker	[5]
CLEC3A	OTTOAEGT	Strong	Biomarker	[6]
MARCHF6	OTBTA03N	Strong	Biomarker	[7]
PSTPIP1	OT4PGEAB	Strong	Genetic Variation	[8]
ROM1	OTE7H0YV	Strong	Biomarker	[9]
------------------------------------------------------------------------------------

References

1	Cefotaxime FDA Label
2	Ceftriaxone FDA Label
3	Post-arthroscopic septic arthritis of the knee. Analysis of the outcome after treatment in a case series and systematic literature review.Eur Rev Med Pharmacol Sci. 2019 Apr;23(2 Suppl):76-85. doi: 10.26355/eurrev_201904_17477.
4	Virulence potential of the staphylococcal adhesin CNA in experimental arthritis is determined by its affinity for collagen.J Infect Dis. 2004 Jun 15;189(12):2323-33. doi: 10.1086/420851. Epub 2004 May 25.
5	Staphylococcus aureus osteoarticular infections in children: an 8-year review of molecular microbiology, antibiotic resistance and clinical characteristics.J Med Microbiol. 2018 Dec;67(12):1753-1760. doi: 10.1099/jmm.0.000859. Epub 2018 Oct 23.
6	Antimicrobial peptides derived from the cartilage.-specific C-type Lectin Domain Family 3 Member A (CLEC3A) - potential in the prevention and treatment of septic arthritis.Osteoarthritis Cartilage. 2019 Oct;27(10):1564-1573. doi: 10.1016/j.joca.2019.06.007. Epub 2019 Jul 4.
7	Outbreak of Septic Arthritis Associated with Intra-Articular Injections at an Outpatient Practice - New Jersey, 2017.MMWR Morb Mortal Wkly Rep. 2017 Jul 28;66(29):777-779. doi: 10.15585/mmwr.mm6629a3.
8	A novel de novo PSTPIP1 mutation in a boy with pyogenic arthritis, pyoderma gangrenosum, acne (PAPA) syndrome.Clin Exp Rheumatol. 2014 Nov-Dec;32(6):956-8. Epub 2014 Jun 24.
9	Outcomes after Total Hip Arthroplasty Using a Cementless S-ROM Modular Stem for Patients with High Hip Dislocation Secondary to Hip Pyogenic Arthritis.Orthop Surg. 2019 Jun;11(3):460-466. doi: 10.1111/os.12485.